Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck's KEYTRUDA ...
Keytruda, known scientifically as pembrolizumab, is an immunotherapy drug that has transformed cancer treatment for many patients worldwide. Traditional chemotherapy works by directly attacking the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results